Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

SU11274

Catalog No: tcsc0144

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
658084-23-2

Formula:
$C_{28}H_{30}ClN_5O_4S$

Pathway:
Protein Tyrosine Kinase/RTK;Autophagy

Target:
c-Met/HGFR;Autophagy

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
PKI-SU11274

Observed Molecular Weight:
568.09

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

SU11274 is a selective **Met** inhibitor with **IC_{50}** of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

IC50 & Target: IC50: 10 nM (Met)[1]

In Vitro: SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3β. SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC_{50} of 50 of 1-1.5 μM. In H69 and H345 cells which have functional Met receptor, SU11274 inhibits the HGF-induced cell growth with IC_{50} of 3.4 μM and 6.5 μM, respectively. SU11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5 μM, and induces caspase-dependent apoptosis by 24% at 1 μM[2]. SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC_{50} values of 0.8-4.4 μM, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling[3].